Current development of adeno-associated viral vectors.
Vectors based on adeno-associated virus (AAV) have recently been used in phase I clinical trials for the treatment of neurological disorders, such as Parkinson's and Canavan's diseases. Indeed, AAV-mediated gene transfer is a promising tool for the delivery of therapeutic gene into the central and peripheral nervous systems. AAV-mediated gene transfer was also applied in phase I and phase II clinical trials for the treatment of cystic fibrosis and in phase I clinical trials for the treatment of hemophilia B. Remarkable progress is being reported in the development of AAV-based vectors; however, the design of AAV-derived vectors needs to be improved. As it stands, AAV-mediated gene transfer has a limited capacity in accommodating foreign genes. In addition, some preclinical studies have shown that AAV-derived vectors can cause tumors in animals due to insertional mutagenesis events. This review will discuss perspectives and drawbacks for AAV-based vector systems.